Wanted: One couple, extremely confident in their love for each other, to go to Mars

Dennis Tito wants to give you the trip of a lifetime.

How much do you love your partner? Enough to move in with them? To a house with just under 17 cubic meters of space? And then not leave that house for just over 500 days straight? While drinking your own recycled urine?

If you do, you're odd. But, you may be able to find gainful employment on a spacecraft to Mars. The New Scientist reports:

This week the Inspiration Mars Foundation, a newly formed non-profit organisation, announced plans for a mission to Mars launching on 5 January 2018 and arriving at the planet in August of that year. Dennis Tito, who in 2001 became the first space tourist to visit the International Space Station, heads the foundation. The trip will be funded primarily by philanthropic donations – but Tito has committed to personally covering the first two years of mission development, no matter how much it costs.

"This is not a commercial mission," Tito said at a press conference on 27 February in Washington DC. "Let me guarantee you, I will come out to be a lot poorer as a result of this mission. But my grandchildren will come out to be a lot wealthier through the inspiration that this will give them."

Orbital trajectories shared on Twitter by team member Michael Loucks show plans for a spacecraft to leave Earth, fly past Mars and then come home – all within 501 days. The craft will pass over Mars at a distance of about 160 kilometres carrying a two-person crew, probably a married man and woman who will be paid to make the trip.

I'm hoping the specificity of "married man and woman" is an overreach on the part of the New Scientist, because that would be excluding all the wannabe astronauts who are unmarried or in same sex relationships. Hell, you could probably make the case that there should be a requirement that the explorers be a couple of the same sex. Because 501 days is considerably longer than nine months, and the one thing you don't want any chance of is space babies.

(Kidding, space babies would be awesome, but re-entry would be pretty tricky. An infertile couple could also work, of course.)

The full New Scientist piece makes clear that the trip is no easy task. Even ignoring the psychological troubles of being cooped up with someone you love(d) for almost 18 months, there's radiation, piloting, and then a ten-day orbital deceleration to deal with. And if you pull all of that off, you still don't get to actually go to Mars—just circle it from space. It's like that time a friend of mine was refused entry into the USA because they didn't have the right visa, only, I'd imagine, considerably more annoying.

The lucky couple's above for 501 days. Photograph: Inspiration Mars

Alex Hern is a technology reporter for the Guardian. He was formerly staff writer at the New Statesman. You should follow Alex on Twitter.

Getty Images/ Staff
Show Hide image

The answer to the antibiotics crisis might be inside your nose

The medical weapons we have equipped ourselves with are losing their power. But scientists scent an answer. 

They say there’s a hero in everyone. It turns out that actually, it resides within only about ten percent of us. Staphylococcus lugdunensis may be the species of bacteria that we arguably don’t deserve, but it is the one that we need.

Recently, experts have cautioned that we may be on the cusp of a post-antibiotic era. In fact, less than a month ago, the US Centres for Disease Control and Prevention released a report on a woman who died from a "pan-resistant" disease – one that survived the use of all available antibiotics. Back in 1945, the discoverer of penicillin, Alexander Fleming, warned during his Nobel Prize acceptance speech against the misuse of antibiotics. More recently, Britain's Chief Medical Officer Professor Dame Sally Davies has referred to anti-microbial resistance as “the greatest future threat to our civilisation”.

However, hope has appeared in the form of "lugdunin", a compound secreted by a species of bacteria found in a rather unlikely location – the human nose.

Governments and health campaigners alike may be assisted by a discovery by researchers at the University of Tubingen in Germany. According to a study published in Nature, the researchers had been studying Staphylococcus aureus. This is the bacteria which is responsible for so-called "superbug": MRSA. A strain of MRSA bacteria is not particularly virulent, but crucially, it is not susceptible to common antibiotics. This means that MRSA spreads quickly from crowded locations where residents have weaker immune systems, such as hospitals, before becoming endemic in the wider local community. In the UK, MRSA is a factor in hundreds of deaths a year. 

The researchers in question were investigating why S. aureus is not present in the noses of some people. They discovered that another bacteria, S. lugdunensis, was especially effective at wiping out its opposition, even MRSA. The researchers named the compound created and released by the S. lugdunensis "lugdunin".

In the animal testing stage, the researchers observed that the presence of lugdunin was successful in radically reducing and sometimes purging the infection. The researchers subsequently collected nasal swabs from 187 hospital patients, and found S. aureus on roughly a third of the swabs, and S. lugdunensis on up to 10 per cent of them. In accordance with previous results, samples that contained both species saw an 80 per cent decrease of the S. aureus population, in comparison to those without lugdunin.

Most notably, the in vitro (laboratory) testing phase provided evidence that the new discovery is also useful in eliminating other kinds of superbugs, none of which seemed to develop resistance to the new compound. The authors of the study hypothesised that lugdunin had evolved  “for the purpose of bacterial elimination in the human organism, implying that it is optimised for efficacy and tolerance at its physiological site of action". How it works, though, is not fully understood. 

The discovery of lugdunin as a potential new treatment is a breakthrough on its own. But that is not the end of the story. It holds implications for “a new concept of finding antibiotics”, according to Andreas Peschel, one of the bacteriologists behind the discovery.

The development of antibiotics has drastically slowed in recent years. In the last 50 years, only two new classes of this category of medication have been released to the market. This is due to the fact almost all antibiotics in use are derived from soil bacteria. By contrast, the new findings record the first occurrence of a strain of bacteria that exists within human bodies. Some researchers now suggest that the more hostile the environment to bacterial growth, the more likely it may be for novel antibiotics to be found. This could open up a new list of potential areas in which antibiotic research may be carried out.

When it comes to beating MRSA, there is hope that lugdunin will be our next great weapon. Peschel and his fellow collaborators are in talks with various companies about developing a medical treatment that uses lugdunin.

Meanwhile, in September 2016, the United Nations committed itself to opposing the spread of antibiotic resistance. Of the many points to which the UN signatories have agreed, possibly the most significant is their commitment to “encourage innovative ways to develop new antibiotics”. 

The initiative has the scope to achieve a lot, or dissolve into box ticking exercise. The discovery of lugdunin may well be the spark that drives it forward. Nothing to sniff about that. 

Anjuli R. K. Shere is a 2016/17 Wellcome Scholar and science intern at the New Statesman